We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This systematic review and pooled analysis is intended to provide an improved estimate of the mortality among cancer patients with COVID-19. Previous studies have indicated mortality rates ranging from 3.7% to 61.5%. This analysis gives a pooled odds ratio for mortality of 25.6%.
The authors conclude that increased risk of death from COVID-19 in cancer patients is an independent factor necessitating aggressive preventive measures and optimal management if infection is contracted. Additional reviews would further define subsets of cancer patients at greatest risk.
– Emily Miller, MD
This abstract is available on the publisher's site.
Patients with COVID-19 who have underlying malignancy have a higher mortality rate compared with those without cancer, although the magnitude of such excess risk is not clearly defined. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate among patients with both cancer and COVID-19.
A systematic literature search involving peer reviewed publications, preprints, and conference proceedings up to July 16, 2020 was performed. The primary endpoint was the case fatality rate (CFR), defined as rate of death among patients with cancer and COVID-19. The CFR was assessed with a random effects model, which was used to derive a pooled CFR and its 95% confidence interval (CI).
52 studies, involving a total of 18,650 patients with both COVID-19 and cancer were selected for the pooled analysis. A total of 4,243 deaths were recorded in this population. The probability of death was 25·6% (95% CI 22·0% to 29·9%; I2=48·9%) in this patient population.
Patients with cancer who develop COVID-19 have high probability of mortality. Appropriate and aggressive preventive measures must be taken to reduce the risk of COVID-19 in patients with cancer, and to optimally manage those who do contract the infection.